Phenotype of proliferating epithelial cells Sample Clauses

Phenotype of proliferating epithelial cells. (A) Serial sections of a glomerulus with a collapsing lesion. The epithelial cells ( ) that cover the collapsed segment are strongly CK8-positive. Also most of the parietal epithelial cells (PECs) lining Xxxxxx’x capsule are CK8- positive. Some PECs are CK8-negative (arrowheads). Podocytes cover- ing the collapsed segment stain positive for synaptopodin. (B and C)A double staining for synaptopodin (red) and PAX-2 (blue). Sometimes PAX-2–positive cells were located on top of synaptopodin expressing podocytes (B), whereas in lesions with more sclerosis synaptopodin ex- pression in affected segments was lost. Double positive cells were not present. (D and E) A double staining for vascular endothelial growth factor (VEGF) mRNA and CK8. Podocytes are VEGF-positive and PECs and epithelial cells that are part of an FSGS lesion are CK8- positive. Double positive cells were not present [(A) ×200, detail ×800; (B and C) ×600; (D) ×400; and (E) ×600]. Immunofluorescence microscopy. Kidney fragments were snap-frozen in liquid nitrogen, and 2 lm acetone- fixed cryostat sections were used. Kidney sections were incubated with antibodies directed against synaptopodin, collagen IV chains, and heparan sulfate (HS) species (Ta- ble 1). Detection of the anticollagen antibodies was done using goat antimouse AlexaTM 488 antibodies (Molec- ular Probes, Inc., Leiden, The Netherlands). We have performed double staining for synaptopodin (a marker of differentiated podocytes) and heparan sulfate species with exclusive presence in either Xxxxxx’x capsule or CK8 PAS A B PAX-2 Synaptopodin
AutoNDA by SimpleDocs

Related to Phenotype of proliferating epithelial cells

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Influenza Vaccination The parties agree that influenza vaccinations may be beneficial for patients and employees. Upon a recommendation pertaining to a facility or a specifically designated area(s) thereof from the Medical Officer of Health or in compliance with applicable provincial legislation, the following rules will apply:

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Geological and Archeological Specimens If, during the execution of the Work, the Contractor, any Subcontractor, or any servant, employee, or agent of either should uncover any valuable material or materials, such as, but not limited to, treasure trove, geological specimens, archival material, archeological specimens, or ore, the Contractor acknowledges that title to the foregoing is vested in the Owner. The Contractor shall notify the Owner upon the discovery of any of the foregoing, shall take reasonable steps to safeguard it, and seek further instruction from the Design Professional. Any additional cost incurred by the Contractor shall be addressed under the provision for changed conditions. The Contractor agrees that the Geological and Water Resources Division and the Historic Preservation Division of the Georgia Department of Natural Resources may inspect the Work at reasonable times.

  • Infrastructure Vulnerability Scanning Supplier will scan its internal environments (e.g., servers, network devices, etc.) related to Deliverables monthly and external environments related to Deliverables weekly. Supplier will have a defined process to address any findings but will ensure that any high-risk vulnerabilities are addressed within 30 days.

  • Target Population The Grantee shall ensure that diversion programs and services provided under this grant are designed to serve juvenile offenders who are at risk of commitment to Department.

Time is Money Join Law Insider Premium to draft better contracts faster.